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Division of Acute Disease Epidemiology 

South Carolina influenza surveillance consists of reporting 
the following:
• 	 Laboratory confirmed cases (culture, RT-PCR, 
DFA, IFA): Positive results from confirmatory tests 
should be reported electronically or via an 1129 card 
within 7 days. 
• 	 Laboratory confirmed hospitalizations: Total 
number of laboratory confirmed (viral culture, PCR, 
DFA, IFA) influenza hospitalizations should be 
reported weekly to the regional health department. 
• 	 Laboratory confirmed deaths: Lab confirmed 
influenza deaths (all ages) should be reported to 
DHEC within 7 days.  Starting in January, 2011, 
pediatric influenza deaths will be reportable 
within 24 hours to your regional health 
(Continued on page 2)
Changes in School and Childcare 

Exclusion Lists for the 2010-2011 

School Year 

Michelle L. Myer, MSN, RN, APRN, CPNP 

Epidemiology Nurse Consultant
 
Division of Acute Disease Epidemiology 

After undergoing extensive revision in 2009 based upon 
new guidance from the American Academy of Pediatrics, 
the exclusion lists for the current academic year have only 
minimal changes.  These affect exclusion for diarrhea 
(addition of Norovirus), clarification on exclusion for fever 
and influenza-like illness (ILI), and updating of criteria for 
exclusion of person exposed to pertussis cases or 
outbreaks.
Norovirus 
Norovirus was added as an exclusion criterion this year, 
after many schools and childcare facilities experienced
outbreaks in the past year.  It has always been 
excludable based upon diarrheal symptoms.  The new
wording for school and childcare reads:
Inside: Ask Epi: Long-term Therapy for Lyme 

Disease—or not? 

A thorough review of the complex process of Lyme disease diagnosis and 
treatment and discussion of issues pertaining to post-Lyme syndrome. 
Update on Influenza: What You Need to Know for 
the Upcoming Season 
Kathleen Laico Antonetti, MD 

Medical Consultant Division of Acute Disease Epidemiology 

On August 10, 2010, the World Health Organization declared that, in 
terms of H1N1 influenza, we are now in a post-pandemic phase.  Now 
is the time to reflect on what was an interesting flu season, which exemplified 
the unpredictable nature of influenza, and to prepare for the upcoming season. 
(Continued on page 4)
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department. Influenza deaths are considered lab-
confirmed with results from viral culture, PCR, rapid 
flu tests, DFA, IFA or autopsy results consistent with 
influenza. 
• 	 Positive rapid antigen influenza tests: Summary 
numbers of positive rapid influenza tests and 
influenza type identified should be submitted to the 
regional health department weekly. 
• 	 Novel or avian influenza surveillance: Any novel
(excluding 2009 H1N1) or avian strain should be 
reported immediately by phone. 
• 	 Influenza like illness (ILINet): Sentinel providers 
submit weekly reports of the total number of patients 
seen in a week and the subset number of those 
patients with ILI symptoms by age group. 
Viral culture network: Sentinel providers submit 
specimens to the BOL for viral culture testing. 
In April, 2009, A novel influenza virus, 2009 H1N1, 
emerged. Unlike typical influenza viruses, 2009 H1N1 
persisted throughout the summer months.  Influenza
activity began to increase in September with the season’s 
peak occurring in early October.  Activity began to 
decrease in April and is currently at a low level.  The 
World Health Organization has recently declared a step 
down from Phase 6 to a post-pandemic phase.  The 2009 
H1N1 virus is expected to co-circulate with other seasonal 
strains.  South Carolina statistics for the 2009-10 season 
are shown below and on facing page: 
(Continued on page 3)
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904 culture and RT-PCR positive specimens were reported 
by the Bureau of Labs and other commercial and clinical 
labs. All subtyped influenza A viruses reported were 2009 
H1N1. One influenza B was identified by the BOL. 
Of the 70 providers enrolled in ILINet, 47 reported at 
least once during the season. A subset of approximately 
15 providers has continued to report throughout the 
summer.
South Carolina’s ILI percentage peaked at 6.06% at the 
start of the season and remained above the South 
Atlantic (2.2) baseline through the end of November. 
(See graphic, facing page.)
There were 21,826 positive rapid flu tests from October 
4, 2009 to August 14, 2010.  This compares to 18,188 for 
this period during the 2008-09 season.  The most positive 
rapid tests observed in one week were during the first 
week of the season. 
The 2010-2011 flu season will begin with MMWR Week 40 
on October 3, 2010.  The full version of the Flu Watch will 
resume publication at this time. 
Please visit the DHEC Flu Monitoring website for the 
weekly Flu Watch: http://www.scdhec.gov/health/ 
disease/acute/flu.htm. An end-of-season flu report will 
be also available on this website in September. 
If you have questions about SC influenza surveillance or 
wish to participate in any of our voluntary surveillance 
networks, contact Chasisity Springs at (803) 898-0870. 
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Review of 2009-2010 Flu Season 
The CDC estimated that from April 2009 to April 2010, 
approximately 61 million people in the United States 
contracted H1N1 influenza; 274,000 people were 
hospitalized with H1N1 influenza, and 12,470 people died 
of the disease. In terms of raw numbers, one may say 
that 2009-2010 was a relatively mild year, given the 
estimates that between 3,000 and 49,000 people in the 
US died each of the past 30 years from flu-associated
illness. However, the data by age confirm that people 
younger than 65 years of age have been more severely
affected by novel H1N1 relative to people 65 and older 
compared to seasonal flu.  With seasonal influenza, about 
60% of seasonal flu-related hospitalizations and 90% of 
flu-related deaths occur in people 65 years and older.  
With 2009 H1N1, approximately 90% of estimated 
hospitalizations and 87% of estimated deaths from April 
through April 2010 occurred in people younger than 65 
years of age.  Therefore, in terms of years of life lost, one 
can say that 2009 H1N1 was more formidable. 
H1N1 seemed to “squeeze out” other strains of influenza, 
with little activity demonstrated by other strains.  
However, as H1N1 activity has decreased, sporadic cases 
of H3N2 influenza have occurred.  Iowa recently 
experienced two outbreaks of H3N2 influenza thought to 
be due to the A/Perth/16/2009-like H3N2 virus.  Eleven 
other states have also reported sporadic cases of H3N2 to 
the CDC. As of yet (September 2010), South Carolina has 
not had any reported cases of H3N2 influenza; however, 
these reports remind us of the importance of continued 
surveillance.  DHEC will continue to post weekly updates 
to our Influenza Surveillance via the FluWatch report, 
available at www.scdhec.gov/health/disease/acute/ 
flu.htm. 
Immunization for Current Flu Season
In the upcoming 2010-2011 flu season, the novel H1N1 
strain (A/California/7/2009 H1N1-like) will be contained in 
the seasonal influenza vaccine as will the H3N2 (A/ 
Perth/16/2009).  The third strain in the 2010-2011 
influenza vaccine is the B/Brisbane/60/2008-like. 
For the upcoming season, the Advisory Committee on 
Immunization Practices (ACIP) recommends 
influenza vaccination for all persons six months of 
age and older.  Since the novel H1N1 strain is included 
in the seasonal vaccine, only one injection will be 
required for most patients.  Adults and children over the 
age of nine will need one injection, while children from six 
Source: CDC, 2010a 
months of age to nine years of age may require two 
injections depending on their previous vaccination history.  
(See flow chart, p. 6) 
Another specific product worthy of discussion is the 
Fluzone High-Dose (Sanofi Pasteur), which the FDA 
approved for patients 65 years of age and over.  These 
older patients typically respond to vaccination with lower 
antibody titers to influenza hemagglutinin compared with 
younger adults. Standard dose inactivated trivalent 
influenza vaccines contain a total of 45 micrograms of 
influenza virus hemagglutinin antigen, 15 micrograms of 
each of the three recommended strains.  In contrast, 
Fluzone High-Dose contains a total of 180 micrograms of 
influenza virus hemagglutinin (60 micrograms of each
strain) in the same volume.  Studies among persons 65 
years and over indicated that, compared with standard 
dose Fluzone, preparations of Fluzone High-Dose elicited 
significantly higher hemagglutinin inhibition titers against 
all three influenza virus strains that were included in the 
vaccine.  Whether the higher postvaccine immune 
responses observed among Fluzone High-Dose recipients 
will result in greater clinical protection against influenza is 
still unknown. A three year postlicensure study of the 
vaccine effectiveness of Fluzone High-Dose compared 
(Continued on page 5)
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with standard dose inactivated influenza vaccine was 
begun in 2009 and should be completed in 2012.  The 
ACIP has not expressed a preference for any specific 
licensed inactivated trivalent influenza vaccine, including 
Fluzone High-Dose, for use in persons 65 years of age 
and older. 
Vaccine Safety 
Last year, many people had concerns about vaccine
safety, even though the H1N1 vaccine was produced in 
the same manner as all influenza vaccines.  The CDC 
monitors vaccine safety mainly through two channels. 
First, is the Vaccine Adverse Event Reporting System 
(VAERS). Clinicians and members of the public 
voluntarily report any potentially vaccine related adverse 
events, which are then investigated to determine whether 
an actual association with vaccination exists.  VAERS data 
indicated 82 adverse event reports per 1 million H1N1 
vaccine doses distributed, compared with 47 reports per 1 
million seasonal influenza doses distributed.  However, no 
substantial differences between H1N1 and seasonal 
influenza were noted in the proportion or types of serious 
adverse events reported.  
The second important method the CDC uses to monitor 
vaccine safety is the Vaccine Safety Datalink (VSD).  The 
VSD is collaboration between CDC and eight managed-
care organizations with a total of 9.5 million members, 
which utilizes administrative data and electronic medical 
records to collect information on vaccinations and other 
health-care encounters to monitor vaccine safety.  No
increase in any adverse events under surveillance has 
been seen in VSD data. The CDC will continue to monitor 
influenza vaccine safety throughout the year, and health-
care providers as well as the public are encouraged to
report adverse health events that occur after vaccination. 
During the 2010 influenza season in Australia, the Fluvax 
Junior and Fluvax trivalent inactivated vaccines (CSL 
Biotherapies) were associated with increased frequency of 
fever and febrile seizures in children aged 6 months
through 4 years. Post-marketing surveillance indicated 
increased reports of fever in children aged 5 to 8 years 
after vaccination with Fluvax compared to previous
seasons. An antigenically equivalent 2010-2011 Northern 
Hemisphere seasonal influenza trivalent inactivated 
vaccine, called Afluria (CSL Biotherapies) is approved by 
the Food and Drug Administration for persons greater 
than 6 months of age in the United States.  On August 5, 
2010, the ACIP recommended that the 2010-2011 Afluria 
vaccine not be administered to children aged 6 months 
through 8 years. Other age-appropriate, licensed 
seasonal influenza vaccine formulations should be used 
for prevention of influenza in these children.  If no other 
age-appropriate, licensed inactivated seasonal influenza 
vaccine is available for a child 5 to 8 years who has a 
medical condition that increases his risk for influenza 
complication, Afluria can be used.  However, providers 
should discuss with the parents or caregivers the risks 
and benefits of Afluria before administering this vaccine 
to children aged 5 to 8 years. 
Treatment 
Clinicians should continue to include influenza in their
differential diagnoses when evaluating patients with acute 
respiratory illness. Treatment decisions should not 
be made on the basis of the results of a rapid 
influenza test since these tests have only 
moderate sensitivity. The neuraminidase inhibitors 
oseltamivir and zanamivir are recommended for use 
against currently circulating viruses.  Both the novel A/ 
California/7/2009 H1N1-like and the A/Perth/16/2009-like 
H3N2 demonstrate susceptibility to these medications.  
The adamantanes, amantadine and rimantadine, are not 
recommended because of high levels of resistance to 
these drugs among both the novel H1N1 and the 
currently circulating H3N2.   
Prompt empiric antiviral treatment is 
recommended for patients with clinically 
suspected influenza illness who have illness 
requiring hospitalization; progressive, severe, or 
complicated illness, regardless of previous health 
status; and patients at increased risk for severe
disease. Persons at high risk of influenza complications 
include people aged 65 years and over; young children; 
pregnant women; people with long-term health conditions 
such as asthma, diabetes, heart disease, neurologic and 
neuro-developmental disorders; and people with 
immunosuppressive conditions or taking 
immunosuppressive medications. 
Testing 
As part of continued influenza surveillance, the SC DHEC 
Bureau of Laboratories (BOL) offers influenza testing for:  
• 	 patients with influenza-like illness (ILI) who are 
admitted to hospitals,
• 	 fatalities associated with ILI, and 
(Continued on page 7)
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• patients with ILI seen at facilities participating in the Sentinel Culture Provider Surveillance Network.
Testing outside the above criteria may also be performed at the BOL if public health staff in the Division of Acute Disease 
Epidemiology or the Regional Public Health Epidemiologic Response staff determine that such testing is necessary.
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Notes on Pediatric Seasonal Vaccination Algorithm (facing page) 
* Figure developed by CDC with the American Academy of Pediatrics, Committee on Infectious Diseases. 
† Children who had a laboratory-confirmed 2009 pandemic H1N1 virus infection (e.g., reverse transcription–polymerase 
chain reaction or virus culture specific for 2009 pandemic influenza A(H1N1) virus) are likely to be immune to this 
virus. At provider discretion, these children can have a “Yes” entered at this box, and proceed down the path to the 
next box to determine whether two doses are indicated based on seasonal vaccine history. However, if no test result 
is available and no influenza A(H1N1) 2009 monovalent vaccine was administered, enter “no” here. 
§ Interval between 2 doses is ≥4 weeks. 
Source: CDC, 2010a: http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf
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Long-term Therapy for Lyme Disease — or Not? 

Eric R. Brenner, MD, Medical Epidemiologist
Division of Acute Disease Epidemiology 
At the DHEC Bureau of Disease Control, we regularly receive questions from providers as well as from 
the public regarding the epidemiology and control of infectious diseases of public health importance.  
From time to time we relay in this Epi Notes Ask-Epi column Q&As of potential interest to a wider 
audience. We invite readers to submit questions for future columns to AskEpi@sc.dhec.gov. 
Question regarding long-term antibiotic treatment disease information (Cooper & Feder, 2004).  The 
of Lyme disease (LD): We have had questions from authors concluded that 10 of the 19 gave “accurate 
several patients suffering from various long-standing information” while 9 gave “inaccurate information.”  
somatic problems who, after they had done some This serves as a caution, and emphasizes the 
“Internet research,” inquired as to whether their problems usefulness of referring patients to a source of 
might be related to “chronic Lyme".  They ask whether accurate information such as the CDC site mentioned
they might benefit, as they had seen suggested on above.
several web sites, from a long course of parenteral 3. 	 Lyme Disease in South Carolina: Lyme disease 
antibiotics. What is the current status of such so- has been reportable in South Carolina (SC) for several
called “Long-term therapy” for Lyme disease?  decades (see the official list of reportable diseases for 
Ask Epi's Answer: The short answer to the question is SC at http://www.dhec.sc.gov/administration/library/ 
that there is no evidence that “long-term” therapy CR-009025.pdf). However, the disease is not 
(i.e., many months of parenteral antibiotics) is commonly reported in South Carolina, where only 
beneficial.  Thus, expert guidelines from the Infectious about 90 cases have been detected by the DHEC 
Disease Society of America (IDSA) (ISDA, 2010; disease surveillance system in the last five years. 
Wormser, et al, 2006) as well as guidelines in standard It may be noted that the "officially counted LD 
textbooks (Steele, 2010 in Mandell 7th edition) cases,” whether in SC or elsewhere, may not 
unequivocally recommend against such therapy.  represent all cases that have actually occurred in the 
Below, we offer a somewhat longer answer which population. We recognize that: 
touches on (i) 	 Some cases are never diagnosed; 
(i) issues relating to the reliability of LD information 
(ii) Diagnostic tests are not 100% sensitive;on the web;  
(ii) some special considerations regarding LD in 	 (iii) Reporting is not complete; and  

South Carolina and in the Southeastern United 
 (iv) The CDC "surveillance definition" for LD is quite 
States;  strict and some patient’s presentations that merit 
(iii) selected summary points relating to diagnosis and 	 to be considered as "cases" from a clinical 
treatment of LD; and  management perspective may not meet formal 
(iv) a bit of the “behind-the-scenes story” relating to 	 surveillance "case-counting" criteria.  

the IDSA guidelines.
 However, it is assumed that these limitations do not 
1. 	 Useful information on the Web: Perhaps the best substantially undercount the numbers of reported 
web information about LD can be found on the CDC’s cases each year. 
Lyme page, accessible by typing www.cdc.gov/lyme/ Ecology of Lyme in SC: This said, the situation in 
(CDC, 2010).  Some portions and links on this site are South Carolina is clearly very different from that in 
meant for the public and can help provide patients northeastern states such as Connecticut, 
with reliable information.  Other links are more Massachusetts, Pennsylvania, and (upstate) New 
technical and are aimed at physicians. York, where several thousand cases per year are 
2. 	 Misinformation on the Web: Cooper and Feder reported.  Ixodes scapularis ticks, the vector for the 
conducted an interesting review of 251 LD websites, LD agent Borrelia burgdorferi, are certainly found in 
finding and analyzing 19 that gave general Lyme (Continued on page 9)
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South Carolina.  However, the ecology of these ticks 
is different in the southeast, where they often feed 
on various species of lizards, which, on the average, 
are not as good hosts for B. burgdorferi as are the 
several species of small rodents on which these same
ticks feed in the northeast (Evans, C., SC Bureau of 
Laboratories Entomologist, personal communication 
with the author, September 9, 2010).  Indeed, in, 
some areas of the country, as many as 80 or 90 
percent of I. scapularis may carry B. burgdorferi, 
whereas in SC evidence points to a much smaller 
percentage being carriers.  In several studies in SC, 
the proportions of ticks infected by B. burgdorferi
during transmission season were 0-2% (Gibson, J. J., 
SC State Epidemiologist, personal communication 
with the editor, September 13, 2010).  Thus, I.
scapularis bites in SC fortunately carry a lower risk of 
transmission than do similar bites in the northeast.
4. 	 Special Considerations in the Southeastern 
United States: To some patients, 
the occurrence of classical erythema 
migrans (an expanding annular 
erythematous rash with progressive 
central clearing – “bull's-eye rash”) at 
the site of a tick bite is synonymous
with Lyme disease. However, it is 
now known that in the southeastern 
US an essentially identical looking 
rash can occur following bites of 
Lonestar ticks (see CDC, 2009b) for 
an excellent photo of this tick). 
These ticks are not known to transmit 
B. burgdorferi. The rash following a 
bite from the Lonestar tick has been 
given the name "Southern Tick-
Associated Rash Illness,” or STARI 
(CDC, 2009b). There had been 
earlier suggestions that STARI was 
due to another Borrelia, B. lonestari. 
This now seems to be in doubt and 
though the cause of STARI cases may 
well be another Borrelia species, the 
exact cause remains unknown.  
Fortunately, the rash and 
accompanying symptoms of STARI 
commonly resolve promptly following 
treatment with oral antibiotics. 
5. 	 Ticks, tick-borne diseases, and post-exposure 
prophylaxis (PEP) in brief: The best method for 
preventing infection is to avoid exposure to vector 
ticks. Recommended measures include:  
(i) 	 Use of protective clothing and tick repellents; 
(ii) Checking the body for ticks at least once a day; 
and 
(iii) Prompt removal of attached ticks.  	Ticks must 
attach for 24-72 hours for transmission to occur 
(Wormser, et al, 2006).   
While the IDSA does not recommend routine use of 
antimicrobial treatment testing following recognized 
tick bites, a single dose of doxycycline (200 mg for 
adults, and 4 mg/kg up to maximum of 200 mg for 
children ≤8 years of age) is recommended if all of the 
following exist: 
(i) 	 The attached tick can be identified as an adult or 
nymphal stage Ixodes scapularis that is estimated 
to have been attached for ≥36 hours (recalling 
that most B. burgdorferi are carried by larval or 
Source: CDC, 2010a, p. 62
(Continued on page 10)
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Diagnosing Lyme Disease: from the Final Report of the Lyme Disease Review Panel of the Infectious
Diseases Society of America
Clinical judgment is critical to all responsible medical practice, including the recognition of disease patterns and 
the rational ordering of diagnostic tests and therapy.  However, the point of departure for all clinical assessments 
is to find a “best fit” association between a patient’s illness and a likely diagnosis as established by medical 
evidence.
Based on current research, for patients with nonspecific symptoms that may be seen in many illnesses (such as
subjective complaints of fatigue, musculoskeletal pains and neurocognitive dysfunction), it would be a deviation 
from this “best fit” to attribute such symptoms to Lyme disease in the absence of more specific clinical features or 
laboratory results.
All Lyme-associated clinical findings, even including erythema migrans, can be seen in diseases
other than Lyme disease. Symptoms that are commonly attributed to chronic or persistent Lyme, such as 
arthralgias, fatigue, and cognitive dysfunction, are seen in many other clinical conditions and are, in fact, common 
in the general population.  This remains true whether or not they are also features of Lyme disease. It would 
thus be clinically imprudent to make the diagnosis of Lyme disease using these nonspecific findings
alone. (ISDA, 2010, p. 26)
Ask Epi: Long-term Therapy for Lyme Disease — or Not?
(Continued from page 9)
nymphal stage ticks (Gibson, J. J., personal
communication with editor, September 13, 2010); 
(ii) PEP can be started within 72 hours of the time 
the tick was removed; 
(iii) Ecologic information suggests that the local 
prevalence of infection of such ticks with B.
burgdorferi is ≥20% (a condition not known to 
exist in South Carolina), and  
(v) Administration of doxycycline is not 

contraindicated (Wormser, et al, 2006). 

An excellent Tick Management Handbook (84 pages) 
is available on the web (Stafford, 2007).  The 
monograph is labeled as a “guide for homeowners, 
pest control operators, and public health officials for 
the prevention of tick-associated disease.”
6. 	 Diagnosis in brief -- and Clinical Epidemiology 
Perspectives on Lyme Disease Testing:  As
microbiologic tests for LD are not commonly available 
and are, in any case, of limited practical utility, 
diagnosis of early Lyme disease is commonly based 
on: 
• 	 Recognition of characteristic clinical signs and 
symptoms: fever, headache, fatigue, EM rash; 
• 	 A history of exposure to ticks (especially in an 
endemic area!), and, except for patients with the 
characteristic Erythema Migrans (EM) rash; 
• 	 Positive serological tests.  
While the ISDA does not recommend routine testing 
after tick bites, they note that it would be “clinically 
imprudent to make the diagnosis of Lyme 
disease using … nonspecific findings
alone” (ISDA, 2010, p. 26).  For such testing, the 
CDC (2009a) and the IDSA (2010) recommend a 
sequential 2-step approach (analogous to serological
testing for HIV infection) wherein samples are first 
tested by ELISA, and patients with equivocal or 
positive results are then tested by Western blotting.  
Both tests can be performed on the same blood 
sample (CDC, 2009a).  
The fact that LD is less common in South 
Carolina than in the Northeast also has 
implications regarding the need for Western 
Blot.  That is, in states where the disease is 
common, positive ELISA tests in the right setting 
might well indicate that a patient does have Lyme 
disease. However, in states such as South
Carolina where the disease is uncommon, 
positive screening tests (ELISA or IFA) have a 
low predictive value, are thus more likely to be
false positives, and must be followed-up with a 
more specific confirmatory test. The CDC notes, 
“If the [confirmatory] Western blot is negative, it 
suggests that the first [screening] test was a false 
positive.  Sometimes two types of Western blot are 
performed, IgM and IgG.  Patients who are positive
by IgM but not IgG should have the test repeated a 
(Continued on page 11)
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(Continued from page 10) guidelines should be consulted for details (Steele, 
2010; Wormser, et al, 2006)
few weeks later if they remain ill.  If they are still 
positive only by IgM and have been ill longer than 
one month, this is likely a false positive” (CDC, 
2009a). Recalling Bayes Theorem, in patients with 
very low pretest probability (low prevalence area, 
atypical clinical presentation, etc.), even positive 
ELISA and Western Blot results may be false positives 
(Gibson, J. J., personal communication with editor,
September 13, 2010). 
Finally, the CDC has also warned about the problem 
of diagnostic tests offered by some commercial 
laboratories “whose accuracy and clinical usefulness 
have not been adequately established” by the FDA.  
Patients are encouraged to ”ask their physicians
whether their testing for LD was performed using 
validated and FDA approved methods and whether 
results were interpreted using appropriate 
guidelines” (CDC, 2005).
7. 	 Treatment in brief:  Doxycycline, amoxicillin, or 
cefuroxime are recommended for treatment of adults 
with early localized or early disseminated Lyme 
disease, for whom treatment is typically given for 14-
21 days. Patients with neurologic involvement, 
cardiac, or joint involvement may require other 
regimens and somewhat more prolonged treatment 
(up to 60 days in some instances).  Standard expert 
8. 	 Long-term treatment in brief: Four randomized, 
placebo-controlled, double-blinded trials of antibiotic 
therapy have been conducted in patients who had 
"post-Lyme disease syndrome" (persistent somatic 
complaints even though they had completed a 
recommended course of therapy).  These have been 
published in three articles (Fallon, et al, 2008; 
Klempner, et al, 2001; Krupp, et al, 2003).  All 
concluded that prolonged antibiotic therapy 
“offers no sustained benefit, and has potential 
serious adverse effects” (Marques, 2008).  Based 
on these trials and other clinical and biologic 
considerations, the IDSA guidelines (ISDA, 2010; 
Wormser, et al, 2006) and other authoritative sources 
(Marques, 2008; Steele, 2010) thus unequivocally 
recommend against "long-term antibiotic 
therapy.”
9. 	 Evidence-based practice guidelines for 
physicians: As alluded to above, the most 
authoritative LD guidelines were prepared in 2006 by 
a panel of 14 physicians for the IDSA (Wormser, et 
al, 2006). The panel used the familiar US Public 
Health Service scoring system for grading 
recommendation and the quality of the evidence 
supporting them.  The 2006 guidelines provide a 
thorough review of issues related to diagnosis and 
(Continued on page 12)
Recommendations in the Post–Lyme Disease Syndromes Section of the 2006 Infectious Diseases 

Society of American Lyme Disease Guidelines
 
• 	 There is no well-accepted definition of post–Lyme disease syndrome.  This has contributed to confusion and 
controversy and to a lack of firm data on its incidence, prevalence, and pathogenesis.  In an attempt to 
provide a framework for future research on this subject and to reduce diagnostic ambiguity in study 
populations, a definition for post–Lyme disease syndrome is proposed in these guidelines. Whatever 
definition is eventually adopted, having once had objective evidence of B. burgdorferi infection 
must be a condition sine qua non. Furthermore, when laboratory testing is done to support the original 
diagnosis of Lyme disease, it is essential that it be performed by well qualified and reputable laboratories that
use recommended and appropriately validated testing methods and interpretive criteria.  Unvalidated test 
methods (such as urine antigen tests or blood microscopy for Borrelia species) should not be used (ISDA, 
2010, p. 18).
• 	 To date, there is no convincing biologic evidence for the existence of symptomatic chronic B. burgdorferi 
infection among patients after receipt of recommended treatment regimens for Lyme disease (ISDA, 2010, p.
18). 
• 	 Antibiotic therapy has not proven to be useful and is not recommended for patients with chronic (16 months) 
subjective symptoms after recommended treatment regimens for Lyme (ISDA, 2010, p. 18).
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treatment, and extensive clinical guidance.  The 
statement also offers helpful photos of nymphal and 
adult stage Ixodes scapularis ticks demonstrating 
changes in blood engorgement after various 
durations of attachment..  The guidelines are 
technical in nature, but much information could be 
accessible to an especially interested general reader 
or patient.  
As mentioned, one of the key conclusions in the 
IDSA document is that no real evidence exists
supporting the utility of "long-term" treatment 
for LD. Though there are patients who have long 
term symptoms following LD, there is no evidence 
that these are related in any way to “persistent LD 
infection” requiring or benefiting from months of 
antibiotic treatment.  Further, some patients with 
persistent unexplained symptoms, including some 
whose problems may be related to other conditions
such as chronic fatigue syndrome or fibromyalgia, 
may believe and/or may have been told (i) that they 
have "chronic Lyme disease"; (ii) that chronic Lyme 
disease is common; and (iii) that their condition 
requires a long-course of antibiotics.
Despite evidence to the contrary, inappropriate long-
term antibiotic therapy for “chronic Lyme disease” 
continues.  Members of Lyme disease advocacy 
groups are often convinced of these three points 
above. Further, some physicians have excessively 
promoted the need for “prolonged therapy,” and had 
profited financially from providing such therapy 
despite lack of acceptable evidence that it is needed; 
some have lost their licenses for this practice.  Finally, 
for reasons related to interpretation of LD serological 
tests (see point 6, above), some patients who have 
received months of antibiotics may never even have 
had LD at all!  These patients have thus been 
subjected both to the expense of unproven 
treatments, and to their potential side effects.  
Deaths from such inappropriate therapy have even 
been reported (Patel, Grogg, Edwards, Wright, & 
Schwenk, 2000).  
10. Further saga of the IDSA Lyme disease 
guidelines: Though the 2006 IDSA guidelines were
generally recognized as being authoritative by the 
medical community, they did generate political 
controversy. In 2006, the Attorney General (AG) of 
the State of Connecticut took action against the IDSA 
arguing that the guidelines’ preparation procedures 
had been inappropriate in a number of ways.  
However, a subsequent (2008) review of the matter 
concluded that the motivation of the AG in bringing 
the action against the IDSA appeared to be  “a 
response to the concerns of Lyme disease advocacy 
groups in Connecticut that the IDSA guideline raised 
doubts about the diagnosis of ‘chronic Lyme disease’ 
and discouraged long-term antibiotic therapy” (Klein, 
2008). In any case, as a consequence of the legal 
action, the IDSA agreed to a thorough review of the 
guidelines. This review was conducted by a new 
expert panel of eight (different) physicians.  Lantos 
notes: 
“After multiple meetings, a public hearing, and 
extensive review of research and other 
information, the Review Panel concluded that the 
recommendations contained in the 2006 
guidelines were medically and scientifically 
justified on the basis of all of the available 
evidence and that no changes to the guidelines 
were necessary.” (Final report of the Lyme 
Disease Review Panel of the Infectious Diseases 
Society of America, 2010). 
The ISDA Guidelines, dated in 2010, are available for 
review by clinicians, from the ISDA website: http:// 
www.idsociety.org/uploadedFiles/IDSA/Resources/ 
Lyme Disease/Final Report/IDSA-Lyme-Disease-Final 
-Report.pdf  (ISDA, 2010). 
Conclusion: Excellent information as well as 
misinformation about Lyme disease can readily be found 
on the Internet.  One of the controversies about LD has 
centered on whether prolonged antibiotic therapy is or is 
not useful (i) for patients who have persistent complaints 
even after having been treated with recommended 
regimens for laboratory-confirmed LD, or even (ii) for
certain patients with similar complaints who have actually 
never been rigorously shown to have laboratory-
confirmed LD.  The current expert consensus is that 
prolonged antibiotic therapy is not beneficial and 
is not recommended for either group. 
James “Jerry” Gibson, MD, MPH, SC State Epidemiologist, 
SC DHEC Bureau of Disease Control, and Christopher
Evans, PhD, SC DHEC Bureau of Laboratories 
Entomologist, also contributed to this article.
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Changes in School and Childcare Exclusion Lists for the 2010-2011 School Year
(Continued from page 1)	 school activities or contributing to the spread of illness in 
school, are also excluded.
• Exclude for diarrhea or vomiting attributable to FeverNorovirus until asymptomatic (diarrhea and/or 
vomiting cease). Students have always been excluded for fever 101° F 
(orally) or higher, in the presence of other symptoms of Note: this is the only time where vomiting by itself is 
severe illness, e.g., rash, vomiting, behavior change.  specified as an exclusion criterion for school-aged 
During the 2009 Novel H1N1 Pandemic, exclusion for children.  School children with vomiting and another
Influenza-Like Illness, defined as fever >100° F withexclusion criterion, e.g., feeling too ill to participate in
(Continued on page 14)
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(Continued from page 13)
other signs of illness (sore throat and/or cough), was 
added. 
At the time when the exclusion lists were being revised 
for Summer 2010 posting, the CDC had redefined ILI to 
include “feverishness,” without a temperature being 
specified (Centers for Disease Control and Prevention, 
2009). This definition may again be revised by the CDC, 
and a significant change will warrant further revision of 
the exclusion lists. 
For 2010-2011, the exclusion criteria for Fever and ILI 
read: 
• 	 Exclude for Fever, accompanied by behavior changes 
or other signs and symptoms of illness (such as rash, 
vomiting, diarrhea, earache, irritability, or confusion), 
in students who do not have signs of influenza-like 
illness, until medical evaluation indicates inclusion is 
acceptable. Fever is defined in school children as:
• 	 Oral temperature: 101.0° F or greater 
• 	 Axillary (under the arm) temperature: 100.0° F or 
greater 
• 	 Exclude students, faculty, staff, volunteers, 
etc., with Influenza / Influenza-like Illness or 
ILI, until at least 24 hours after they are free of fever 
or signs of a fever (without the use of fever-reducing 
medicines). ILI is defined as feverishness (an oral 
temperature of 100 degrees Fahrenheit or more) with
a cough and/or sore throat for which there is no 
other known cause besides the flu or an influenza-like 
illness. An ill person has signs of a fever if he or she 
feels warmer than usual to the touch, has a flushed 
appearance, or is sweating or shivering. 
The list of conditions for which exclusion is NOT 
mandated now includes:
• 	 Fever, without any other signs of severe illness, if 
child can participate comfortably in school/program 
activities.
Signs of severe illness include: difficulty breathing; 
unusual lethargy (an unusual tiredness or lack of energy); 
unusually severe irritability, especially in younger 
students; rapidly spreading rash; weeping or draining 
sores that cannot be covered; severe vomiting and 
diarrhea or vomiting blood; and when a student poses a 
risk of spreading a harmful disease to others in the school 
setting.
Exposure to Pertussis Cases
The AAP (2009b, p. 509 and 2009a, p. 156) now 
recommends exclusion of close contacts who are 
coughing until they receive appropriate evaluation and 
treatment.  Previous verbiage in the exclusion lists was 
consolidated to reflect this recommendation.  The revised 
criterion now reads:  
• 	 In outbreaks and when recommended by DHEC, 
exclude exposed people (close contacts to pertussis 
cases) if the contacts are coughing or have other 
symptoms of pertussis.  Contacts with cough illness 
are excluded (1) until after 5 days of antimicrobial 
therapy; (2) for 21 days after last contact with an 
infected person; (3) after a negative pertussis test 
result; or (4) if a healthcare provider indicates that 
illness is not pertussis.  
Symptoms of pertussis include a new or different cough, 
that is may be accompanied by vomiting after cough, loss 
of breath or difficulty catching breath during coughing 
spells, cyanosis, a whoop when inhaling after coughing, 
or apneic episodes in infants. 
The Exclusion Lists may be accessed on the DHEC 
website at www.scdhec.gov/health/disease/ 
exclusion.htm. There you will find detailed information 
on exclusion for school and childcare for healthcare and 
school professionals, printable brochures for parents, and 
HTML pages readable on personal assistive devices.  
Parent brochures are available in English and Spanish.
Please contact the Division of Acute Disease Epidemiology 
if you have questions regarding exclusion, outbreaks, or 
other illness in schools or out-of-home childcare. 
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Year-to-Date Summary of Reportable Conditions‡ – January 1 to August 1, 2010
Disease/Condition
Case Status
Total
Confirmed Probable
Animal Bite - PEP Recommended** 206 * 206 
Aseptic meningitis 52 0 52 
Campylobacteriosis 166 0 166 
Cryptosporidiosis 48 18 66 
Cyclosporiasis 2 0 2 
Dengue Fever 3 2 5 
Ehrlichiosis, chaffeensis 4 1 5 
Giardiasis 78 0 78 
Group A Streptococcus, invasive 79 0 79 
Group B Streptococcus, invasive 33 0 33 
Haemophilus influenzae, invasive 58 0 58 
Hepatitis (not otherwise specified) 1 0 1 
Hepatitis A, acute 19 0 19 
Hepatitis B virus infection, Chronic 41 228 269 
Hepatitis B, acute 35 0 35 
Hepatitis C Virus Infection, past or present 1,899 13 1,912
Influenza, Rapid Test 2,723 0 2,723
Influenza, human isolates 26 0 26 
Legionellosis 9 0 9 
Leptospirosis 0 1 1 
Listeriosis 9 0 9 
Lyme disease 12 6 18 
Malaria 3 0 3 
Mumps 3 0 3 
Neisseria meningitidis, invasive (Mening. disease) 9 0 9 
Novel Influenza A Virus Infections 201 0 201 
Pertussis 190 23 213 
Q fever 0 2 2 
Salmonellosis 577 2 579 
Scombroid fish poisoning 1 0 1 
Shiga toxin-producing Escherichia coli (STEC) 9 1 10 
Shigellosis 41 0 41 
Spotted Fever Rickettsiosis 0 7 7 
Strep pneumoniae, invasive 333 0 333 
Streptococcus pneumoniae, invasive disease (IPD) 1 0 1 
Toxic-shock syndrome, staphylococcal 1 0 1 
Varicella (Chickenpox) 73 1 74 
Vibrio parahaemolyticus 1 0 1 
Vibrio spp., non-toxigenic, other or unspecified 8 0 8 
Vibrio vulnificus infection 1 0 1 
Yersiniosis 3 0 3 
‡ To save space, conditions with zero reported cases in 2010 were omitted from this list. 
*   Animal bites with PEP recommended: Bat-45; Cat-47; Dog-62; Farm Animal-0; Fox-12; Raccoon-29; Skunk-5; Other-6. 
** Probable case status is not allowed for this condition.
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